BMS
Bristol-Myers Squibb’s Yervoy scores EU approval in paediatric melanoma
January 23, 2018Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, EU, Yervoy, pharma
Bristol-Myers Squibb has revealed that its immunotherapy Yervoy (ipilimumab) has received an expanded indication from the European Commission, approving the …
BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer
October 13, 2017Sales and Marketing BMS, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, NICE, opdivo, pharma, pharmaceutical
Thanks to successful negotiation of a managed access agreement, NICE has announced its recommendation of Bristol-Myers Squibb’s Opdivo (nivolumab) for …
BMS left red-faced as Opdivo+Yervoy fails to beat rival Pfizer drug in kidney cancer
August 16, 2017Research and Development BMS, Kidney cancer, Yervoy, life sciences, opdivo, pharma, pharmaceutical
Bristol-Myers Squibb has been left somewhat red-faced after its combination of Opdivo (nivolumab) and Yervoy (ipilimumab) failed to show any …
Bristol-Myers Squibb’s $2.3 billion gamble to boost cancer pipeline
August 4, 2017Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, IFM Therapeutics, biotech, drugs, pharma, pharmaceutical
Bristol-Myers Squibb has agreed a deal to acquire IFM Therapeutics for a potential $2.3 billion. The latter is a biotech …
BMS vet joins Kleo Therapeutics as CEO
June 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Kleo Pharmaceutical
Kleo Pharmaceutical has moved to appoint industry veteran Doug Manion to the position of CEO. Kleo are a biotech company …
SMC reverses decision on Opdivo for kidney cancer
June 12, 2017Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, SMC, opdivo
The Scottish Medicines Consortium (SMC) has performed a U-turn on its decision regarding Opdivo (nivolumab), and will now allow patients …
BMS and Array BioPharma partner up to tackle colorectal cancer
May 30, 2017Manufacturing and Production, Research and Development, Sales and Marketing Array Biopharma, BMS, Bristol-Myers Squibb
Bristol-Myers Squibb and Array BioPharma have announced they are to join forces as part of a new clinical research partnership …
England “really is not a good place” to get cancer, BMS UK General Manager says
April 24, 2017Medical Communications, Research and Development, Sales and Marketing BMS, NICE, opdivo
Bristol-Myers Squibb’s UK General Manager Ben Hickey has slammed NICE over its assessment criteria and process in recommending access to …
NICE turns down BMS’ Opdivo for head and neck cancer
April 11, 2017Manufacturing and Production, Sales and Marketing BMS, NICE, opdivo
Bad news for Bristol-Myers Squibb as NICE chooses not to recommend its immunotherapy drug Opdivo (nivolumab) for use in head …
Asia-Pacific NSCLC market to more than double to $6.2bn by 2023
March 21, 2017Manufacturing and Production, Research and Development, Sales and Marketing BMS, Eli Lilly, MSD, NSCLC, Yervoy, keytruda, opdivo
New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific …
NICE recommends against Opdivo for classical Hodgkin lymphoma
March 15, 2017Research and Development, Sales and Marketing BMS, classical Hodgkin Lymphoma, opdivo
The National Institute of Health and Care Excellence (NICE) has released draft guidance provisionally turning down Bristol-Myers Squibb’s Opdivo (nivolumab) …
Immunotherapy: The three major treatments that are changing cancer prognoses
March 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Cancer, MSD, Roche, immunotherapy, keytruda, oncology, opdivo, tecentriq
The promise of Immunotherapy as a game-changer for cancer treatment has been evident since its advent in the space. However, …
BMS finds replacement for retiring CSO
March 9, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb
Bristol-Myers Squibb has announced the appointment of Dr. Thomas J. Lynch, Jr., to the position of Executive Vice President and …
BMS temporarily expands Board with three new additions
February 23, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb
Bristol-Myers Squibb has bolstered its Board of Directors with the appointment of three Directors, a move which temporarily expands its …
MSD aims to get the jump on BMS treating bladder cancer
February 6, 2017Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, MSD, keytruda, opdivo
Bristol-Myers Squibb’s Opdivo was only just approved for second-line treatment of bladder cancer, but MSD has attempted to have its …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
